JATT II Acquisition Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $100.3M
- Price
- $13.38
- % Change (Daily % change from the live per-ticker quote feed.)
- +7.04%
- Volume
- 8.6K
About
JATT II Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in healthcare and healthcare-related businesses. The company was incorporated in 2026 and is based in Westfield, New Jersey.
Quick stats
Shares outstanding8.0M
Computed float5.9M
Float / shares73.8%
Key info
SectorFinancial Services
IndustryShell Companies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002112446
AI Summary
AI-generated1/3
majorbullishm and a
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases
JATT II Acquisition Corp. entered into a definitive business combination agreement with Talawar Therapeutics, a biotech firm developing bispecific antibodies for immunology and inflammatory diseases.
The transaction is expected to provide $285 million in pro forma cash, comprising $60 million from JATT II's trust and a $225 million PIPE priced at $10.00 per share led by Access Biotechnology and Bain Capital Life Sciences.
Talawar's lead asset TALA-125 targets atopic dermatitis and is slated for clinical entry in Q1 2027, with funds expected to support operations through a Phase 2b data readout in H2 2028.